or
Remember me
Back
Strategic Healthcare Leap: Adnexus Biotechnologies and Sanctum Therapeutics Unite for Breakthrough HIV and SARS-CoV-2 Treatments
Adnexus Biotechnologies Inc., a staking target of 1606 Corp. (OTC PINK: CBDW), has announced a game-changing merger with Sanctum Therapeutics. This partnership aligns the cutting-edge AI-driven capabilities of Adnexus with Sanctum's innovative therapeutic assets, aiming to redefine the landscape of HIV and SARS-CoV-2 treatment.
Receive investor kits and email updates from Stockhouse and directly from these companies.